Risk factors
Nautilus Biotechnology (NAUT) risk factors
Item 1A of every Nautilus Biotechnology, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors61 risks3 new5 dropped8 reworded
Nautilus updated its financial figures showing a net loss of $59.0 million for 2025 and an accumulated deficit of $332.0 million. The company transitioned from an emerging growth company to a smaller reporting company under the Exchange Act. The commercialization strategy for the Nautilus Voyager platform was clarified to include an Early Access Program using a cloud platform.
Filed Feb 26, 2026 - FY2024 10-K risk factors63 risks
Nautilus Biotechnology faces pre-revenue risks as it develops its proteomics platform, relying heavily on single-source suppliers and third-party collaborators.
Filed Feb 27, 2025